Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.


Player Avatar Haaldan (63.64) Submitted: 1/2/2013 4:33:43 AM : Outperform Start Price: $4.70 EXEL Score: -99.70

Good time to buy for this company. It's been bouncing between $4.50 and $5.00 for quite some time, and now that it has revenue, it should bounce back easily.

Featured Broker Partners